Welcome to our dedicated page for Net Medical news (Ticker: NMXS), a resource for investors and traders seeking the latest updates and insights on Net Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Net Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Net Medical's position in the market.
Net Medical (OTC PINK:NMXS) has launched a clinical trial program for medical device manufacturers seeking FDA Emergency Use Authorization (EUA) or 510K clearance. This initiative aims to help companies navigate regulatory processes to sell products in the U.S. market. Utilizing their proprietary Telemed software and a CLIA authorized laboratory, Net Medical is uniquely positioned to support manufacturers through compliance challenges. The company has also achieved a notable third place in the FDA's Designathon contest for COVID-19 reporting, showcasing the effectiveness of their technology in real-world applications.
Net Medical (OTC PINK:NMXS) announces the launch of statewide testing in support of the federal Test-to-Treat Program. This initiative, led by Chief Medical Officer Dr. Neeraj Dubey, aims to provide a free home telemedicine program for COVID-19 testing. Patients will have access to antiviral pills and monoclonal antibodies, enhancing treatment effectiveness, especially if symptoms arise within the first two days. Initial rollout targets Arizona, Pennsylvania, and New Mexico with the potential for expansion. More details on their Telemed platform and services are available.
Net Medical (OTC PINK:NMXS) reported significant growth in 2021, achieving revenues of $1.768 million, up 58% from $1.118 million in 2020. The company also recorded a net income of $10,000, compared to a loss of $499,000 the previous year. CEO Dick Govatski highlighted the positive impact from new medical laboratory services and the successful launch of mobile COVID testing labs in New Mexico. As 2022 progresses, the company is exploring further testing programs and potential expansions, particularly in relation to the Federal government's Test to Treat initiative.
Net Medical (OTC PINK:NMXS) has announced the launch of a new product line under the brand Immunity Science, set to debut by the end of March 2022. This line will feature anti-inflammatory supplements including zinc, quercetin, and vitamins C and D. The offerings aim to support immune health and target issues like colds, flu, and inflammation, in response to increased consumer awareness post-COVID-19. The new website for Immunity Science will facilitate online sales. CEO Dick Govatski emphasizes the growing consumer demand for health-boosting products.
Net Medical Xpress Solutions (OTC PINK:NMXS) reported strong preliminary results for the fourth fiscal quarter of 2021, achieving a net income of $301,285 and total revenue of $821,399.
The company experienced high demand for COVID testing through its advanced mobile testing labs, utilizing bioMerieux's proprietary PCR testing for rapid, certified results. This FDA-approved test can detect 22 viral pathogens, including COVID-19, influenza, and the common cold.
Net Medical Xpress Solutions (OTC PINK: NMXS) announced the launch of mobile PCR testing vans in New Mexico, providing efficient and free testing for Covid, influenza, and other upper respiratory infections. Utilizing bioMerieux's proprietary testing technology, the service allows rapid detection of 22 viral pathogens, addressing public health needs amidst the ongoing pandemic. The initiative has seen high demand, prompting plans for similar programs in other states. CEO Dick Govatski emphasized the importance of fast, reliable testing in today's health climate.
Net Medical has launched 'Gold Standard PCR' testing for COVID-19, flu, and cold-related infections in New Mexico, leveraging mobile testing vans in Albuquerque and Taos. The initiative utilizes bioMerieux's proprietary PCR testing module, ensuring rapid and accurate results for the public. CEO Dick Govatski reported high demand for testing services, which are provided free of charge. Following successful implementation, the company plans to expand testing services to additional states, addressing the ongoing health information needs amid the pandemic's transition to endemic status.
Net Medical Xpress Solutions (OTC PINK:NMXS) has initiated Covid testing under an agreement with the New Mexico Department of Health. The company will provide rapid antigen and PCR tests at multiple sites, along with a licensed physician and CLIA-certified laboratory facilities for specimen processing. Their mobile testing units can test up to 700 persons daily and include certified result documentation. Chief Medical Officer Dr. Neeraj Dubey noted that these services are already enhancing revenue and cash flow, showcasing the company's growth in the telemedicine and testing sectors.